"武田" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonJapan's Takeda says Q3 profit slid 38%, trailing analyst estimates - Reuters
Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates Reuters
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenu...
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and ...
Takeda's Triple Win: Stellar Earnings, Cash Flow Boost, and Massive Buyback Plan Revealed - Stock...
Takeda's Triple Win: Stellar Earnings, Cash Flow Boost, and Massive Buyback Plan Revealed StockTitan
Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda - BioSpace
Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda BioSpace
Takeda’s Earnings Call Reveals Mixed Performance, Optimistic Outlook - TipRanks
Takeda’s Earnings Call Reveals Mixed Performance, Optimistic Outlook TipRanks
Takeda bids adieu to Uloric after gout med's gradual fade from glory - FiercePharma
Takeda bids adieu to Uloric after gout med's gradual fade from glory FiercePharma
Takeda regains home rights to depression drug from Neurocrine - Fierce Biotech
Takeda regains home rights to depression drug from Neurocrine Fierce Biotech
Takeda Pharmaceutical Expected to Post Lower Third-Quarter Net Profit -- Earnings Preview - Marke...
Takeda Pharmaceutical Expected to Post Lower Third-Quarter Net Profit -- Earnings Preview MarketWatch
Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates -January 30, 2025 at 01:43 am ...
Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates -January 30, 2025 at 01:43 am EST Marketscreener.com
Neurocrine revamps osavampator deal with Takeda - The Pharma Letter
Neurocrine revamps osavampator deal with Takeda The Pharma Letter
FANUC cobot boosts H&S for Takeda Pharmaceutical Co. - The Manufacturer
FANUC cobot boosts H&S for Takeda Pharmaceutical Co. The Manufacturer
ViewPoints: Takeda gastro chief tells how new biomarker project could help INTERCEPT Crohn's dise...
ViewPoints: Takeda gastro chief tells how new biomarker project could help INTERCEPT Crohn's disease FirstWord Pharma
Takeda 2024 Annual Integrated Report | Better Health for People, Brighter Future for the World - ...
Takeda 2024 Annual Integrated Report | Better Health for People, Brighter Future for the World Takeda Pharmaceuticals
Takeda and Boston Medical Center Partner to Cut Health Care Emissions - American Hospital Associa...
Takeda and Boston Medical Center Partner to Cut Health Care Emissions American Hospital Association
Takeda tightens reins on early-stage investments, looks to expand option deals: R&D head - Fierce...
Takeda tightens reins on early-stage investments, looks to expand option deals: R&D head Fierce Biotech
Fierce Pharma Asia—Takeda R&D chief's new strategy; AZ, Daiichi's ADC nod; Fosun's failed Henlius...
Fierce Pharma Asia—Takeda R&D chief's new strategy; AZ, Daiichi's ADC nod; Fosun's failed Henlius buy FiercePharma
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sal...
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales FiercePharma
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment - MarketWatch
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment MarketWatch
Neurocrine Amends License Agreement with Takeda - TipRanks
Seller's remorse? Takeda reacquires Japanese rights to depression candidate from Neurocrine - Fir...
Seller's remorse? Takeda reacquires Japanese rights to depression candidate from Neurocrine FirstWord Pharma
Global CSR Program 2023: University of Nairobi - Takeda Pharmaceuticals
Global CSR Program 2023: University of Nairobi Takeda Pharmaceuticals
Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn - AFTD
Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn AFTD
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - Investing.com
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal Investing.com
Building on 240 years of innovation through business development | Takeda Stories - Takeda Pharma...
Building on 240 years of innovation through business development | Takeda Stories Takeda Pharmaceuticals
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Ther...
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics Business Wire
Vaccine Business Unit leader's path began in dengue ward | Takeda Stories - Takeda Pharmaceuticals
Vaccine Business Unit leader's path began in dengue ward | Takeda Stories Takeda Pharmaceuticals
We exceeded our 50% sustainable paper packaging goal | Takeda Stories - Takeda Pharmaceuticals
We exceeded our 50% sustainable paper packaging goal | Takeda Stories Takeda Pharmaceuticals
Aetna takes Takeda to court over ‘anticompetitive scheme’ with generic drugs - Endpoints News
Aetna takes Takeda to court over ‘anticompetitive scheme’ with generic drugs Endpoints News
Access to Medicines - Strengthening Healthcare Systems - Takeda Pharmaceuticals
Access to Medicines - Strengthening Healthcare Systems Takeda Pharmaceuticals
Aiming to enhance regulatory submissions with GenAI | Takeda Stories - Takeda Pharmaceuticals
Aiming to enhance regulatory submissions with GenAI | Takeda Stories Takeda Pharmaceuticals
Global CSR Program 2023: SFH Rwanda - Takeda Pharmaceuticals
Global CSR Program 2023: SFH Rwanda Takeda Pharmaceuticals
Takeda plans drug launches and hiring for 2025 - The Business Journals
Takeda plans drug launches and hiring for 2025 The Business Journals
Takeda - International Organization for Migration (IOM)
Takeda International Organization for Migration (IOM)
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Trans...
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug - BioSpace
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug BioSpace
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plan...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans FiercePharma
Takeda Announces Subsidiary Liquidation and Merger Completion - Yahoo Finance
Takeda Announces Subsidiary Liquidation and Merger Completion Yahoo Finance
Takeda's oral TYK2 inhibitor matches biologic efficacy - Drug Discovery & Development
Takeda's oral TYK2 inhibitor matches biologic efficacy Drug Discovery & Development
Japan's Takeda raises full-year profit forecast amid restructuring - Reuters
Japan's Takeda raises full-year profit forecast amid restructuring Reuters
MIT-Takeda Program wraps up with 16 publications, a patent, and nearly two dozen projects complet...
MIT-Takeda Program wraps up with 16 publications, a patent, and nearly two dozen projects completed MIT News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated ...
Amgen, Biogen and Takeda talk about R&D on tough targets - STAT
Amgen, Biogen and Takeda talk about R&D on tough targets STAT
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration - BioSpace
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration BioSpace
How Takeda Pharmaceuticals Accelerates Large-Scale Bioinformatics with AWS HealthOmics - AWS Blog
How Takeda Pharmaceuticals Accelerates Large-Scale Bioinformatics with AWS HealthOmics AWS Blog
Joining forces to develop a multidisciplinary care model in GI| Takeda Stories - Takeda Pharmaceu...
Joining forces to develop a multidisciplinary care model in GI| Takeda Stories Takeda Pharmaceuticals
In psoriatic arthritis, connections matter | Takeda Stories - Takeda Pharmaceuticals
In psoriatic arthritis, connections matter | Takeda Stories Takeda Pharmaceuticals
The true burden of celiac disease: Bill’s journey | Takeda Stories - Takeda Pharmaceuticals
The true burden of celiac disease: Bill’s journey | Takeda Stories Takeda Pharmaceuticals
How Community Health Workers help build health Equity | Takeda Stories - Takeda Pharmaceuticals
How Community Health Workers help build health Equity | Takeda Stories Takeda Pharmaceuticals
Innovating to address neglected tropical diseases (NTDs) | Takeda Stories - Takeda Pharmaceuticals
Innovating to address neglected tropical diseases (NTDs) | Takeda Stories Takeda Pharmaceuticals
Takeda Belgium welcomes Bruno Rabilier as New General Manager for Commercial Operations - Takeda ...
Takeda Belgium welcomes Bruno Rabilier as New General Manager for Commercial Operations Takeda Pharmaceuticals
Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl - Fierce Biotech
Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl Fierce Biotech
Assistance program reaches patients across Mexico | Takeda Stories - Takeda Pharmaceuticals
Assistance program reaches patients across Mexico | Takeda Stories Takeda Pharmaceuticals
Takeda stops phase 2 post-anesthesia recovery trial over slow enrollment - Fierce Biotech
Takeda stops phase 2 post-anesthesia recovery trial over slow enrollment Fierce Biotech
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO -January 23, 2025 at 07:24 pm...
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO -January 23, 2025 at 07:24 pm EST Marketscreener.com
A children’s book raises awareness of hemophilia in Kazakhstan | Takeda Stories - Takeda Pharmace...
A children’s book raises awareness of hemophilia in Kazakhstan | Takeda Stories Takeda Pharmaceuticals
Takeda gets crafty with $1.2B biobucks deal to create molecular glues with Degron - Fierce Biotech
Takeda gets crafty with $1.2B biobucks deal to create molecular glues with Degron Fierce Biotech
MIT-Takeda Program uses AI to unlock innovation | Takeda Stories - Takeda Pharmaceuticals
MIT-Takeda Program uses AI to unlock innovation | Takeda Stories Takeda Pharmaceuticals
The virus hunters: "driven to make medicines safer " | Takeda Stories - Takeda Pharmaceuticals
The virus hunters: "driven to make medicines safer " | Takeda Stories Takeda Pharmaceuticals
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Benzinga
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Benzinga
Takeda presents positive proof-of-concept results for IgAN patients - European Pharmaceutical Man...
Takeda presents positive proof-of-concept results for IgAN patients European Pharmaceutical Manufacturer
Takeda details another round of layoffs in Massachusetts as restructuring drive rolls on - Fierce...
Takeda details another round of layoffs in Massachusetts as restructuring drive rolls on FiercePharma
Can wearable technology help in sleep disorder diagnosis? | Takeda Stories - Takeda Pharmaceuticals
Can wearable technology help in sleep disorder diagnosis? | Takeda Stories Takeda Pharmaceuticals
Teva, Takeda sell generics joint venture in Japan to focus on innovative drugs - FiercePharma
Teva, Takeda sell generics joint venture in Japan to focus on innovative drugs FiercePharma
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture...
How a conversation led to a new AI assistant | Takeda Stories - Takeda Pharmaceuticals
How a conversation led to a new AI assistant | Takeda Stories Takeda Pharmaceuticals
The importance of partnership: A conversation with Takeda - The Catalyst (PhRMA)
The importance of partnership: A conversation with Takeda The Catalyst (PhRMA)
Takeda’s revenue climbs by 14.1% in Q1 FY2024 - Pharmaceutical Technology
Takeda’s revenue climbs by 14.1% in Q1 FY2024 Pharmaceutical Technology
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and ...
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator Marketscreener.com
Takeda wins Japan Classic after 6 playoff holes - ESPN
Rare disease called cTTP poses challenge for new mom | Takeda Stories - Takeda Pharmaceuticals
Rare disease called cTTP poses challenge for new mom | Takeda Stories Takeda Pharmaceuticals
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCET...
Takeda is fourth big company to leave BIO since December - STAT
Takeda is fourth big company to leave BIO since December STAT
Why Takeda no longer has an 'IT department' as part of the drug maker's digital and data transfor...
Takeda Pharmaceuticals Announces Multi-Target Collaboration Up to $1.2 Billion with Degron Therap...
Takeda Pharmaceuticals Announces Multi-Target Collaboration Up to $1.2 Billion with Degron Therapeutics Ropes & Gray LLP
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Dataset...
Takeda drug for rare types of epilepsy misses goal in late-stage trial - BioPharma Dive
Takeda drug for rare types of epilepsy misses goal in late-stage trial BioPharma Dive
US allows increased production of Takeda's ADHD drug and its generics to address shortage - Reuters
US allows increased production of Takeda's ADHD drug and its generics to address shortage Reuters
Preserving a 1,500-year-old hollyhock festival in Japan |Takeda Stories - Takeda Pharmaceuticals
Preserving a 1,500-year-old hollyhock festival in Japan |Takeda Stories Takeda Pharmaceuticals
Takeda hires Jane Woo as head of R&D, portfolio comms - PR Week
Takeda hires Jane Woo as head of R&D, portfolio comms PR Week
Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024 -...
Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024 BioSpace
Zambia’s first family medicine program overcomes the odds | Takeda Stories - Takeda Pharmaceuticals
Zambia’s first family medicine program overcomes the odds | Takeda Stories Takeda Pharmaceuticals
Goodbye Wave: Takeda axes Huntington’s pact, freeing partner to pursue fresh interest - Fierce Bi...
Goodbye Wave: Takeda axes Huntington’s pact, freeing partner to pursue fresh interest Fierce Biotech
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: A...
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst Yahoo Finance
Takeda's seizure drug fails to meet main goal in late-stage studies - Reuters
Takeda's seizure drug fails to meet main goal in late-stage studies Reuters
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? - Yahoo Finance
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? Yahoo Finance
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colo...
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC) Yahoo Finance
Neurocrine Amends Collaboration with Takeda on Osavampator -January 27, 2025 at 05:30 pm EST - Ma...
Neurocrine Amends Collaboration with Takeda on Osavampator -January 27, 2025 at 05:30 pm EST Marketscreener.com
CEO Annual Letter to Shareholders - Takeda Pharmaceuticals
CEO Annual Letter to Shareholders Takeda Pharmaceuticals
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - BioSpace
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook BioSpace
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy ...
Takeda Joins Hot Molecular Glue Market With $1.2B Deal - BioSpace
Takeda Joins Hot Molecular Glue Market With $1.2B Deal BioSpace
Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook - Yahoo Finance
Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook Yahoo Finance
Takeda hires FleishmanHillard veteran Anne de Schweinitz for global role - PR Week
Takeda hires FleishmanHillard veteran Anne de Schweinitz for global role PR Week
Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Ag...
How Takeda accelerated the financial close process by nearly two weeks - EY
How Takeda accelerated the financial close process by nearly two weeks EY
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist ...
Takeda taps longtime FleishmanHillard alum to head up global corporate brand and content - Fierce...
Takeda taps longtime FleishmanHillard alum to head up global corporate brand and content FiercePharma
What going digital means for Takeda - EY
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Tak...